Abstract 141P
Background
Patients with unresectable upper GI cancers have limited therapies and a dismal prognosis. While granting access to additional treatments, enrollment in phase I trials offers unclear benefits in this population.
Methods
Individual patient data of subjects with advanced upper GI cancers receiving ≥1 dose of the study drug within phase I trials at SCRI UK between 2011-2023 were collected. Objective response rate (ORR: CR+PR), clinical benefit rate (CBR: % with any tumor shrinkage), and disease control rate (DCR: CR+PR+SD) were assessed by RECIST v1.1, and progression-free survival (PFS) and overall survival (OS) from trial start. Outcomes were reported using descriptive statistics and uni- and multivariate analyses. Subjects participating in more than one trial (n=20) were assessed separately in each study.
Results
Of 1796 patients screened, 104 patients with upper GI cancers (65% esophageal/junctional; 35% gastric) from 35 phase I trials were included. Most were male (75%), had adenocarcinoma (91%), and stage IV at diagnosis (73%). At trial entry, median age was 61 (range 20-86), median number of prior lines 2 (range 1-4), and median number of metastatic sites 2 (range 1-5). Seventy-four (60%), 37 (30%), and 13 (10%) received immunotherapy (IO), small molecules, or antibody-drug conjugates, respectively; 27 (22%) received a molecularly matched therapy. Median follow-up was 14.8 months (95% CI, 10.39-68.15). ORR was 17% (95% CI, 0.10-0.26), CBR 43% (95% CI, 0.33-0.53), and DCR 87% (95% CI, 0.79-0.93) across all trials. Efficacy was comparable by number of prior lines, trial drugs, or allocation to matched therapy. In response-evaluable patients across all trials (n=100), median OS and PFS were 12.3 (95% CI, 7.77-16.88) and 2.9 months (95% CI, 2.45-3.40), respectively, and were significantly longer for responders versus non-responders (both p<0.001). Depth of response, low metastatic burden (≤2 sites), and IO combos remained significant predictors of improved survival in multivariate analysis.
Conclusions
Participation in phase I trials offers substantial benefits in refractory upper GI cancers regardless of biomarker selection with compelling results in late-line settings and potential early access to newly approved therapies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract